Alexion Pharmaceuticals, Inc. focuses on the development and commercialization of life-transforming drugs for treating patients suffering from ultra-rare disorders. Soliris approved for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome is the key product of this New Haven, CT-based company. In this scenario, investors focus should remain on Soliris performance.
Under its metabolic franchise, the company markets Strensiq for the treatment of patients with pediatric-onset hypophosphatasia (HPP) and Kanuma for the treatment of patients with lysosomal acid lipase deficiency (LAL-D).
The company’s track record has been impressive. Over the last four quarters, the company has beaten estimates on all four occasions. Overall, Alexion has posted an average positive earnings surprise of 15.21% for the trailing four quarters.
Currently, Alexion has a Zacks Rank #2 (Buy), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Alexion surpassed earnings expectations in the first quarter of 2018. Our consensus called for EPS of $1.29, and the company reported EPS of $1.68.
Revenue: Revenues, also, beat expectations. Alexion posted revenues of $930.9 million, compared to our consensus estimate of $918 million.
Key Stats: Soliris sales increased 2.1% in the quarter to $800.1 million. During the quarter the company launched Soliris in the United States for the treatment of refractory generalized myasthenia gravis (gMG) in patients who are anti-acetylcholine receptor antibody-positive. The company also announced positive top line results from the phase III study of its long-acting C5 complement inhibitor- ALXN1210 which showed that patients with paroxysmal nocturnal hemoglobinuria (PNH) can be effectively and safely switched from treatment with Soliris every two weeks to treatment with ALXN1210 every eight weeks.
2018 Guidance: The company raised its earnings per share and revenue guidance for 2018. It expects earnings per share to be in the range of $6.75 to $6.90 up from the previous range of $6.60 to $6.80. It projects revenues to be in the range of $3.93 to $3.99 billion up from its previous expectation of $3.85 to $3.95 billion. The Zacks Consensus Estimate for earnings for 2018 was $6.90 per share while for sales it was $3.99 billion.
Share Price Impact:There was no movement in pre-market trading.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market. Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Image: Bigstock
Alexion (ALXN) Tops Q1 Earnings and Sales Beat Estimates
Alexion Pharmaceuticals, Inc. focuses on the development and commercialization of life-transforming drugs for treating patients suffering from ultra-rare disorders. Soliris approved for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome is the key product of this New Haven, CT-based company. In this scenario, investors focus should remain on Soliris performance.
Under its metabolic franchise, the company markets Strensiq for the treatment of patients with pediatric-onset hypophosphatasia (HPP) and Kanuma for the treatment of patients with lysosomal acid lipase deficiency (LAL-D).
The company’s track record has been impressive. Over the last four quarters, the company has beaten estimates on all four occasions. Overall, Alexion has posted an average positive earnings surprise of 15.21% for the trailing four quarters.
Currently, Alexion has a Zacks Rank #2 (Buy), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Alexion surpassed earnings expectations in the first quarter of 2018. Our consensus called for EPS of $1.29, and the company reported EPS of $1.68.
Revenue: Revenues, also, beat expectations. Alexion posted revenues of $930.9 million, compared to our consensus estimate of $918 million.
Key Stats: Soliris sales increased 2.1% in the quarter to $800.1 million. During the quarter the company launched Soliris in the United States for the treatment of refractory generalized myasthenia gravis (gMG) in patients who are anti-acetylcholine receptor antibody-positive. The company also announced positive top line results from the phase III study of its long-acting C5 complement inhibitor- ALXN1210 which showed that patients with paroxysmal nocturnal hemoglobinuria (PNH) can be effectively and safely switched from treatment with Soliris every two weeks to treatment with ALXN1210 every eight weeks.
2018 Guidance: The company raised its earnings per share and revenue guidance for 2018. It expects earnings per share to be in the range of $6.75 to $6.90 up from the previous range of $6.60 to $6.80. It projects revenues to be in the range of $3.93 to $3.99 billion up from its previous expectation of $3.85 to $3.95 billion. The Zacks Consensus Estimate for earnings for 2018 was $6.90 per share while for sales it was $3.99 billion.
Share Price Impact:There was no movement in pre-market trading.
Alexion Pharmaceuticals, Inc. Price and EPS Surprise
Alexion Pharmaceuticals, Inc. Price and EPS Surprise | Alexion Pharmaceuticals, Inc. Quote
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market. Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>